Michael A. Choti, MD, chief of surgery at MD Anderson Cancer Center, discusses some controversial topics he sees in the treatment landscape of metastatic colorectal cancer.
Michael A. Choti, MD, chief of surgery at MD Anderson Cancer Center, discusses some controversial topics he sees in the treatment landscape of metastatic colorectal cancer (mCRC).
When metastases in patients with mCRC can potentially be resected, Choti says patients may still be offered a curative intent therapy over a surgical resection of the primary tumor. When there is a limited number of lung metastases or liver metastases in a patient, surgical therapy to resect those sites of disease should be offered.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More